Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 2/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20610183 | 0.83 | NPC1 (0.35) | GAANPC1RAB9ACA12CA9 | |
| SCHEMBL20610248 | 0.82 | POLB (0.34) | CYP1A2GAA | |
| SCHEMBL20610181 | 0.82 | NPC1 (0.39) | GAANPC1RAB9ACA12CA9 | |
| SCHEMBL20610209 | 0.82 | NPC1 (0.39) | GAANPC1RAB9ACA12CA9 | |
| SCHEMBL17422537 | 0.82 | PTGS2 (0.40) | NPC1RAB9ACA12CA9COMT | |
| SCHEMBL29679797 | 0.82 | PTGS2 (0.40) | NPC1RAB9ACA12CA9COMT | |
| SCHEMBL31534727 | 0.82 | PTGS2 (0.40) | NPC1RAB9ACA12CA9COMT | |
| SCHEMBL20610201 | 0.82 | NPC1 (0.36) | CYP1A2GAANPC1RAB9ACA12 | |
| SCHEMBL20610238 | 0.81 | CYP1A2 (0.32) | CYP1A2GAA | |
| SCHEMBL20610221 | 0.79 | CYP1A2 (0.32) | CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131177-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2020-04-30 | — | — | US | disclosed |
| US-20200131177-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2020-04-30 | — | — | US | disclosed |
| WO-2019008115-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131177-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | DDT, ACHE, SQOR | CYP1A2 71/4885GAA 3463/4885NPC1 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.